Investigate the value of plasma galectin-3 and RANKL measurements in predicting disease progression and skeletal complications in Multiple Myeloma

Project Details


The aim is to study the changes in Galectin-3 & RANKL during disease transition from asymptomatic smouldering myeloma to clinically aggressive symptomatic myeloma to identify ‘markers’ that predict disease progression
Effective start/end date2/10/232/10/24

Collaborative partners

  • University of Northampton (lead)
  • University of Liverpool
  • Science and Technology, University of Northampton
  • Department of Haematology Peterborough City Hospital


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.